Literature DB >> 11159190

Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects.

E Montgomery1, M Goggins, S Zhou, P Argani, R Wilentz, M Kaushal, S Booker, K Romans, P Bhargava, R Hruban, S Kern.   

Abstract

The tumor-suppressor protein Dpc4 (Smad4, Madh4) regulates gene expression. On binding of an extracellular ligand of the extensive transforming growth factor (TGF) superfamily to its cognate receptor complex, latent cytoplasmic Dpc4 is activated and translocated into the nucleus to function as part of various DNA-binding transcriptional activator complexes. The most relevant ligand/receptor pair to control the tumor suppressive function of Dpc4 remains uncertain, but is usually assumed to be TGF-beta and its heteromeric receptor. We exploited a fortuitous experiment of nature to directly test this hypothesis: the TGF-beta type II receptor gene is inactivated by mutation in nearly all colorectal carcinomas having microsatellite instability, as seen in hereditary nonpolyposis colorectal cancer (HNPCC) and in sporadic medullary colorectal cancers. Using a specific and sensitive immunohistochemical label for Dpc4, we examined nuclear localization of Dpc4 in 13 HNPCC, six medullary, and 41 sporadic nonmedullary colorectal carcinomas. In agreement with published rates, two (5%) of 41 sporadic tumors showed complete loss of Dpc4 protein, indicative of genetic inactivation. All 13 HNPCC and six medullary tumors had intact cytoplasmic and nuclear Dpc4 localization. The TGFBR2 gene was sequenced in three of the cancers from patients with HNPCC, and all of these harbored inactivating mutations. The specificity of the immunohistochemical assay was demonstrated in xenograft tumors of syngeneic cell lines that differed in DPC4 genetic status because of an engineered gene knockout. Thus, nuclear localization of Dpc4 can be maintained in cells with inactivated TGF-beta type II receptors, suggesting the persistence of tumor-suppressive action of an upstream signaling input, most likely a ligand/receptor complex distinct from TGF-beta. Identification of the relevant input would be expected to have implications for the understanding of tumorigenesis and the design of rational biological therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159190      PMCID: PMC1850322          DOI: 10.1016/s0002-9440(10)63995-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  25 in total

1.  Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.

Authors:  R E Wilentz; G H Su; J L Dai; A B Sparks; P Argani; T A Sohn; C J Yeo; S E Kern; R H Hruban
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

2.  BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications.

Authors:  M Goggins; R H Hruban; S E Kern
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

3.  Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity.

Authors:  R E Wilentz; M Goggins; M Redston; V A Marcus; N V Adsay; T A Sohn; S S Kadkol; C J Yeo; M Choti; M Zahurak; K Johnson; M Tascilar; G J Offerhaus; R H Hruban; S E Kern
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

4.  Transforming growth factor-beta responsiveness in DPC4/SMAD4-null cancer cells.

Authors:  J L Dai; M Schutte; R K Bansal; R E Wilentz; A Y Sugar; S E Kern
Journal:  Mol Carcinog       Date:  1999-09       Impact factor: 4.784

5.  Osteogenic protein-1, a bone morphogenic protein member of the TGF-beta superfamily, shares chemotactic but not fibrogenic properties with TGF-beta.

Authors:  A E Postlethwaite; R Raghow; G Stricklin; L Ballou; T K Sampath
Journal:  J Cell Physiol       Date:  1994-12       Impact factor: 6.384

6.  Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences.

Authors:  H Kim; J Jen; B Vogelstein; S R Hamilton
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

7.  The relationship of quantitative nuclear morphology to molecular genetic alterations in the adenoma-carcinoma sequence of the large bowel.

Authors:  J W Mulder; G J Offerhaus; E P de Feyter; J J Floyd; S E Kern; B Vogelstein; S R Hamilton
Journal:  Am J Pathol       Date:  1992-10       Impact factor: 4.307

8.  Pathology of hereditary non-polyposis colorectal cancer.

Authors:  J R Jass; T C Smyrk; S M Stewart; M R Lane; S J Lanspa; H T Lynch
Journal:  Anticancer Res       Date:  1994 Jul-Aug       Impact factor: 2.480

9.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.

Authors:  S Markowitz; J Wang; L Myeroff; R Parsons; L Sun; J Lutterbaugh; R S Fan; E Zborowska; K W Kinzler; B Vogelstein
Journal:  Science       Date:  1995-06-02       Impact factor: 47.728

10.  A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability.

Authors:  L L Myeroff; R Parsons; S J Kim; L Hedrick; K R Cho; K Orth; M Mathis; K W Kinzler; J Lutterbaugh; K Park
Journal:  Cancer Res       Date:  1995-12-01       Impact factor: 12.701

View more
  6 in total

1.  SMAD4 protein expression and cell proliferation in colorectal adenocarcinomas.

Authors:  Adriana Handra-Luca; Sylviane Olschwang; Jean-François Fléjou
Journal:  Virchows Arch       Date:  2011-10-16       Impact factor: 4.064

2.  Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival.

Authors:  Aatur D Singhi; Tyler J Foxwell; Katie Nason; Kristi L Cressman; Kevin M McGrath; Weijing Sun; Nathan Bahary; Herbert J Zeh; Ryan M Levy; James D Luketich; Jon M Davison
Journal:  Am J Surg Pathol       Date:  2015-04       Impact factor: 6.394

3.  Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers.

Authors:  Shih-Chang Chuang; King-Teh Lee; Kun-Bow Tsai; Pai-Ching Sheen; Eishi Nagai; Kazuhiro Mizumoto; Masao Tanaka
Journal:  World J Surg       Date:  2004-09-29       Impact factor: 3.352

4.  The role of SMAD4 in early-onset colorectal cancer.

Authors:  S G Royce; K Alsop; A Haydon; L Mead; L D Smith; A A Tesoriero; G G Giles; M A Jenkins; J L Hopper; M C Southey
Journal:  Colorectal Dis       Date:  2009-01-27       Impact factor: 3.788

5.  TGFbeta modulates PTEN expression independently of SMAD signaling for growth proliferation in colon cancer cells.

Authors:  Jimmy Y C Chow; Jennifer A Cabral; Jessica Chang; John M Carethers
Journal:  Cancer Biol Ther       Date:  2008-10-22       Impact factor: 4.742

6.  Colorectal carcinoma tumour budding and podia formation in the xenograft microenvironment.

Authors:  Friedrich Prall; Claudia Maletzki; Maja Hühns; Mathias Krohn; Michael Linnebacher
Journal:  PLoS One       Date:  2017-10-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.